title: [Picrotoxin in the treatment of Menière's disease].
abstract: OBJECTIVE
  In medical long-term treatment of Menière's disease picrotoxin suppositories are an uncommon method of prophylaxis. In spite of its empirical benefit in clinical use and its lack of side effects, there are few clinical studies about the therapeutical effect of picrotoxin. In this study we evaluate the effectiveness of picrotoxin compared to the therapy with betahistine in Menière's disease.
  
  
  METHODS
  In a prospective clinical trial we examined 41 patients, 18 of them were treated with betahistine 3x12 mg, 23 had a therapy with picrotoxin-suppositories at 0.001 g three times a week. Frequency and intensity of the vertigo attacks were evaluated before and under treatment. Mean follow up time was 12 months.
  
  
  RESULTS
  In both groups a reduction of the attacks' frequency and intensity could be noticed, which was statistically significant for all the two groups. Thus, in the course of the treatment we observed a significant stronger effectiveness of picrotoxin, regarding the frequency and intensity of vertigo attacks. Discussing our own results we review the state of the art in medical long-term treatment in Menière's disease.
  
  
  CONCLUSIONS
  Because of its clinical benefit and the lack of side effects Picrotoxin is a reasonable alternative in medical long- term treatment of Menière's disease, which should have an important role in the treatment cascade.
authors: Hals-Nasen-Ohrenklinik und Poliklinik Universitätsmedizin Berlin, Charité, Campus Mitte, Berlin. sebastian.weikert@charite.de
authors: S
authors: S
authors: Weikert
authors: A
authors: A
authors: Rotter
authors: H
authors: H
authors: Scherer
authors: M
authors: M
authors: Hölzl
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001621:Betahistine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D010852:Picrotoxin / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D013488:Suppositories
chemical_list: D001621:Betahistine; D010852:Picrotoxin; D013488:Suppositories